Angiotensin converting enzyme inhibitors in perspective: an update.

Abstract

Orally active inhibitors of angiotensin converting enzyme (ACE) have made a major impact on the clinical therapy of hypertension, congestive cardiac failure and ventricular remodelling after myocardial infarction. The ACE inhibitors combine the advantages of efficacy and low incidence of side effects, with the promise of cardio-, vasculo- and reno- protection.